FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Following the completion of the study, all 6 defining IPDAS criteria, all 6 certification criteria, and 20 of 23 quality criteria were met with the drafted patient aid. Following alpha testing, 11 urologists, 7 patients previous receiving surgery, 3 patient advocates, and 1 methodological expert reviewed the aid and answered the quality survey. A vast majority of total members agreed that the language was easy to follow, had appropriate length, balanced presentation of options, high-quality decisional tool, and useful tool for new patients. Particularly, the aid’s strengths were the simple language, graphics, and concept.
At the conclusion of her presentation, Dr. McAlpine discussed that this type of decision aid should be implemented at all practicing urology fields. There was a high satisfaction in this study’s sample size and the concept could be easily expanded to other fields. In future studies, however, a randomized control trial and decision aid for patients with small renal masses should be carried out.
Presented by: Kristen McAlpine, Division of Urology, University of Ottawa, Ottawa, ON, Canada
Co-Authors: Rodney Breau1,2, Dawn Stacey2, Christopher Knee1,2, Luke Lavallee1,2
1Division of Urology, University of Ottawa, Ottawa, ON, Canada; 2The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Written by: Zachary Valley, MD, twitter: @ZacharyAValley), (Department of Urology, University of California-Irvine) at the 73rd Canadian Urological Association Annual Meeting - June 23 - 26, 2018 - Halifax, Nova Scotia